期刊
PLATELETS
卷 33, 期 2, 页码 192-199出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/09537104.2021.1962519
关键词
Antiplatelet drugs; coagulation; COVID-19; platelets; thrombosis
COVID-19 is a pandemic caused by SARS-CoV-2 infection, leading to inflammation and thrombosis. Targeting the altered platelet activation state may be beneficial, with some antiplatelet drugs showing promising results.
Coronavirus disease 2019 (COVID-19) is a pandemic syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 infection induces a process of inflammation and thrombosis supported by an altered platelet activation state. This platelet activation is peculiar being characterized by the formation of platelet-leukocytes rather than platelet-platelet aggregates and by an increased procoagulant potential supported by elevated levels of TF positive platelets and microvesicles. Therapeutic strategies targeting, beyond systemic inflammation (i.e. with tocilizumab, an anti interleukin-6 receptor), this state of platelet activation might therefore be beneficial. Among the antithrombotic drugs proposed as candidates to treat patients with SARS-CoV-2 infection, antiplatelet drugs, such as aspirin are showing promising results.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据